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Introduction
In 2010, there were 1.8 million deaths among the 34 million 
people infected with the human immunodeficiency virus 
(HIV).1 Of these deaths, 1.2 million occurred in the 22.9 mil-
lion HIV-infected Africans.1 Antiretroviral therapy (ART) has 
transformed HIV infection into a manageable chronic condi-
tion and the World Health Organization (WHO) currently 
recommends ART for individuals with a CD4+ T lymphocyte 
(CD4 cell) count ≤ 350 cells/µL.2 In 2010, 42% of the 9 million 
individuals in need of treatment globally were receiving ART.3 
Unfortunately, in low-income countries patients are started on 
ART at lower CD4 cell counts than in high-income countries: 
in 2006, the median count was reported to be 108 cells/µL 
and 234 cells/µL in these two types of countries, respectively.4 
Moreover, after adjusting for immunodeficiency at baseline, 
mortality during the first months of ART was higher in low-
income countries than in high-income countries.4,5 High mor-
tality rates early in ART have been documented in Africa,6 the 
Caribbean,7 Latin America7 and south-eastern Asia.8,9 Conse-
quently, additional interventions are needed to decrease early 
mortality during ART in low- and middle-income countries.
Cotrimoxazole contains two antibiotics: sulfamethoxazole 
and trimethoprim. Cotrimoxazole provides good coverage 
against gram-positive bacteria (e.g. Streptococcus pneumoniae), 
gram-negative bacteria (e.g. Escherichia coli and non-typhoid 
Salmonella), protozoa (e.g. Isospora belli, Toxoplasma gondii 
and Plasmodium falciparum) and fungi (e.g. Pneumocystis 
jirovecii). The patent for cotrimoxazole has expired and it costs 
around 7 United States dollars for 1 year of daily therapy.10 
In high-income countries, cotrimoxazole is used in adults 
with HIV infection as chemoprophylaxis against P. jirovecii 
pneumonia and T. gondii infection.11 Randomized trials 
that included ART-naïve Africans found that cotrimoxazole 
improved survival while reducing the risk of malaria, pneu-
monia, sepsis, isosporiasis, T. gondii encephalitis, wasting and 
Kaposi’s sarcoma.12–14 However, a Senegalese trial that used 
half the recommended adult cotrimoxazole dose reported no 
mortality benefit in ART-naïve adults.15 A study in Uganda 
showed that treating HIV-infected adults with cotrimoxazole 
and ART reduced mortality in their uninfected children and 
the number of orphans.16
In settings where the health-care infrastructure is limited, 
WHO recommends cotrimoxazole for adults with WHO clini-
cal stage 2, 3 or 4 HIV infection.17 If the prevalence of HIV 
infection is high, however, WHO recommends that all infected 
adults be treated because cotrimoxazole reduces morbidity 
irrespective of clinical disease stage or CD4 cell count and 
because it simplifies cotrimoxazole distribution.17
Common causes of mortality in adults receiving ART in 
low- and middle-income countries include sepsis, tuberculosis, 
Crytptococcus neoformans meningitis, T. gondii encephalitis, 
P. jirovecii pneumonia, Kaposi’s sarcoma and chronic diar-
rhoea.6,18–20 Given the results of earlier trials,12–14 cotrimoxazole 
may decrease both mortality and morbidity in adults with HIV 
infection, regardless of ART status. The aim of this study was 
to carry out a systematic review of the effect of cotrimoxazole 
on mortality and morbidity in individuals aged 13 years or 
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more who were receiving ART for an 
HIV infection.
Methods
This systematic review was conducted 
in accordance with PRISMA (Preferred 
Reporting Items for Systematic Reviews 
and Meta-Analyses) guidelines.21 The 
PubMed and Embase databases were 
searched systematically in December 
2010 for randomized controlled tri-
als and prospective and retrospective 
cohort studies on the effect of daily 
cotrimoxazole in HIV-infected indi-
viduals aged 13 years or more who were 
receiving ART. The search strategies 
(Table 1, available at: http://www.who.
int/bulletin/volumes/90/2/11-093260) 
were designed with a specialist librarian 
and there were no language, publication 
or date restrictions. The primary out-
come of interest was death. Secondary 
outcomes were hospitalization, incident 
events synonymous with WHO clinical 
stage 3 or 4 HIV disease, incident ma-
laria events and adverse events leading 
to hospitalization or cotrimoxazole ces-
sation. The Cochrane Central Register of 
Controlled Trials and the International 
Standard Randomized Controlled Trial 
Number Register were searched using 
the terms “cotrimoxazole” and “antiret-
roviral therapy”.
The abstracts of all publications 
identified were reviewed independently 
by two of the authors (ABS and AVR). 
The full texts of all articles selected 
by one or both reviewers were then 
matched against the inclusion criteria 
and articles satisfying these criteria were 
included in the review (Fig. 1, available 
at: http://www.who.int/bulletin/vol-
umes/90/2/11-093260). The references 
of all articles that met the inclusion 
criteria were also considered for incor-
poration into the systematic review.
Data were extracted from the 
articles included in the review using a 
standardized spreadsheet. The informa-
tion collected included the name of the 
article’s first author, the year of publica-
tion, the study’s methods and design, the 
study population, the study intervention 
and control intervention, the duration of 
follow-up, inclusion and exclusion cri-
teria, primary and secondary outcomes, 
and losses to follow-up.
In accordance with the recommen-
dations of the Cochrane Collaboration,22 
the Newcastle–Ottawa Quality Assess-
ment Scale was used to identify bias 
in the cohort studies.23 This scale rates 
studies from 0 to 9 using eight criteria 
that cover three sources of bias: selec-
tion, confounding and measurement 
bias. Each criterion is worth one point 
except confounding bias, which is worth 
two points. Selection bias was assessed 
using four criteria: (i) the patient cohort 
receiving cotrimoxazole and ART was 
representative of adults receiving this 
treatment in the community from which 
the cohort was drawn; (ii) the cohort 
receiving ART alone was representative 
of the cohort on both cotrimoxazole 
and ART; (iii) cotrimoxazole use had 
been ascertained; and (iv) the majority 
of study participants were known to be 
asymptomatic (i.e. had WHO clinical 
stage 1 or 2 disease) at study baseline. A 
study was regarded as having addressed 
confounding due to the baseline level 
of immunodeficiency if the results had 
been adjusted for the baseline CD4 cell 
counts. Measurement bias was assessed 
using three criteria: (i) all deaths were 
validated; (ii) there was adequate follow-
up to detect cotrimoxazole’s preventive 
effect on death (i.e. a median or mean 
follow-up period of at least 3 months), 
and (iii) ≤ 20% of study participants 
were lost during follow-up. A score of 7 
to 9 indicated high methodological qual-
ity, a score of 4 to 6 indicated moderate 
quality, and a score of 0 to 3 indicated 
low quality.
Publication bias was evaluated us-
ing a funnel plot, with the treatment 
effect measure on the x-axis and the 
standard error of the log of the effect 
measure on the y-axis (details are avail-
able from the corresponding author on 
request). Egger’s and Begg’s tests were 
used to assess the symmetry of the fun-
nel plot. Since the studies were similar 
enough to combine, a meta-analysis was 
performed and statistical heterogene-
ity was assessed. Effect measures were 
quantified as the natural log of the effect 
measure and the standard error24 as:
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Since both χ2 and tau statistical tests 
of the heterogeneity of the magnitude of 
a treatment effect across studies depend 
on knowledge of the number of events in 
each study arm and this information was 
not available for all studies that met the 
inclusion criteria, an I-squared statistic 
was used. In practice, the I-squared 
statistic is calculated by subtracting the 
number of degrees of freedom from the 
Q-statistic and then dividing the result 
by the Q-statistic.25 Values of I-squared 
less than 25% indicate low heterogene-
ity, values near 50% indicate moderate 
heterogeneity and values above 75% in-
dicate high heterogeneity.26 A random-
effects statistical model is preferred 
when I-squared is ≥ 25%.27
Since the value of I-squared ob-
tained for the studies included in 
this analysis was greater than 25%, a 
random-effects model was used to de-
rive a summary estimate of the effect of 
cotrimoxazole on mortality. The possible 
causes of the observed heterogeneity, 
including the duration of follow-up and 
the percentage of participants who had 
WHO stage 3 or 4 disease at baseline, 
were explored by a sensitivity analysis. 
Unfortunately, neither the baseline viral 
load nor the baseline CD4 cell count 
could be included in the sensitivity 
analysis because data on the baseline 
viral load were not collected in most 
studies and data on the median or mean 
baseline CD4 cell count were collected 
in only four of the seven eligible studies 
reporting on the primary outcome. All 
analyses were performed using Stata ver-
sion 10.0 (StataCorp. LP, College Station, 
United States of America).
Results
Details of the study participants and 
study designs described in the nine ar-
ticles included in the systematic review 
are shown in Table 2 and Table 3, respec-
tively. Of the nine, seven reported an es-
timate for the effect of cotrimoxazole on 
mortality,28–34 whereas three reported an 
estimate for the effect on morbidity.28,35,36 
Two studies also reported the preven-
tive effect on malaria.28,36 Assessment 
of publication bias indicated that three 
studies28–30 were of high methodologi-
cal quality, while the other six31–36 were 
of moderate methodological quality 
(Table 4, available at: http://www.who.
int/bulletin/volumes/90/2/11-093260). 
In addition, one on-going trial inves-
tigating when to stop cotrimoxazole 
during ART was identified.37 That trial 
involves 2000 individuals in Uganda 
and has a randomized, double-blind, 
placebo-controlled non-inferiority 
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design. Its aim is to test the hypothesis 
that stopping cotrimoxazole in adults 
on ART will not increase morbidity or 
mortality and will decrease haemato-
logical adverse events. The results are 
due in 2014.
The effect of cotrimoxazole on 
mortality reported in the seven stud-
ies in the meta-analysis is illustrated 
in Fig. 2. Begg and Egger P-values for 
publication bias in the studies were 0.29 
and 0.49, respectively, which suggests 
the absence of publication bias. The 
summary estimate of the effect of cotri-
moxazole on the incidence rate of death 
derived using a random-effects model 
was 0.42 (95% confidence interval, CI: 
0.29–0.61). Survival was increased by 
either continuing cotrimoxazole at ART 
initiation,29,33–35 initiating cotrimoxazole 
at the same time as ART29,34 or initiat-
ing cotrimoxazole when the patient was 
stable on ART.28,30
The Q-statistic and the I-squared 
statistic for the seven studies reporting 
on the primary outcome were 102.3 
and 93.2%, respectively, indicating high 
heterogeneity.26 A sensitivity analysis 
that evaluated the effect of the median 
or mean number of years of follow-up 
indicated that the length of the study did 
not explain the heterogeneity (P = 0.85). 
Nor was the percentage of participants 
with symptomatic HIV infection (i.e. 
WHO stage 3 or 4 disease) at baseline 
found to provide an explanation on 
sensitivity analysis (P = 0.91).
Regarding cotrimoxazole’s effect on 
morbidity, Walker et al. reported that 
cotrimoxazole resulted in a reduction 
in the odds of malaria (odds ratio, OR: 
0.74; 95% CI: 0.63–0.88).28 This effect 
was maintained throughout a follow-up 
period of 5 years. In addition, Walker 
et al. also reported that cotrimoxazole 
reduced the odds of new or recurrent 
WHO clinical stage 3 or 4 disease events 
(OR: 0.85; 95% CI: 0.74–0.98),28 whereas 
Miiro et al. reported a trend towards 
lower all-cause morbidity (relative risk, 
RR: 0.66; 95% CI: 0.41–1.06), although 
all-cause morbidity was undefined.35 A 
trial identified during the review of ref-
erences of studies that met the inclusion 
criteria found that the risk of both ma-
laria (RR: 0.04; 95% CI: 0.01–0.17) and 
diarrhoea (RR: 0.56; 95% CI: 0.43–0.77) 
was lower among Ugandans on ART 
who were randomized to cotrimoxazole 
than among those who were not.36 The 
patients had been receiving ART for a 
mean of 3.7 years, their median CD4 cell 
count was 489 cells/µL and 94% had a 
viral load < 400 RNA copies/mL.
Two studies gave details of adverse 
events associated with cotrimoxazole. 
Walker et al. reported 22 serious cotri-
moxazole-related adverse events during 
8128 person–years of treatment: all were 
either haematological adverse events, 
rash or hypersensitivity.28 Lowrance 
et al. reported that 10 of 574 patients 
on cotrimoxazole stopped treatment 
during 6 months of follow-up but did 
not state whether or not the cause was 
cotrimoxazole-related toxicity.30
Since only two of the eight studies 
followed participants for more than 
13 months on average, it was difficult 
to gauge whether or not the survival 
benefit of cotrimoxazole waned after 
ART-induced immune reconstitution. 
However, Walker et al. did analyse the 
effect of the duration of cotrimoxazole 
combined with ART.28 They found that 
cotrimoxazole was associated with a 
substantial reduction in the odds of 
death between weeks 1 and 12 of the 
administration of cotrimoxazole com-
bined with ART (OR: 0.41; 95% CI: 
0.27–0.65) and that the reduction was 
sustained between weeks 12 and 72 (OR: 
0.56; 95% CI: 0.37–0.86) but ceased to 
be evident after week 72 (OR: 0.96; 95% 
CI: 0.63–1.45). There was no evidence of 
variation in this effect resulting from an 
updated CD4 cell count.
It was also difficult to determine 
whether the survival benefit of cotri-
moxazole was influenced by the base-
line CD4 cell count since in six studies 
most participants initiated ART with a 
CD4 cell count of less than 200 cells/
µL. However, Hoffmann et al. reported 
that the reduction in the hazard of death 
was substantial among individuals with 
a baseline CD4 cell count less than 
200 cells/µL (hazard ratio, HR: 0.64; 95% 
CI: 0.56–0.72) and those with a baseline 
count between 200 and 350 cells/µL 
(HR: 0.62; 95% CI: 0.41–0.94) but was 
not significant among those with a count 
greater than 350 cells/µL at baseline 
(HR: 0.80; 95% CI: 0.38–1.70).29
Discussion
This systematic review indicates that 
cotrimoxazole reduced mortality in 
individuals aged 13 years or more who 
were receiving ART. The summary 
estimate of the effect of cotrimoxazole 
on the incidence rate of death was 0.42 
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was no evidence of publication bias in 
the studies included in the review, there 
was significant heterogeneity in the find-
ings: the I-squared statistic was 93.2%. 
Unfortunately, only a limited sensitivity 
analysis could be performed because of 
differences in the variables recorded in 
the various studies. Nonetheless, the 
sensitivity analysis showed that neither 
symptomatic HIV infection (i.e. WHO 
stage 3 or 4 disease) nor the duration of 
follow-up explained the heterogeneity.
Cotrimoxazole is safe, well toler-
ated, widely available and inexpensive. 
Although cotrimoxazole can help reduce 
the high early mortality rate in HIV-
infected adults on ART in low- and 
middle-income countries, it is still not 
widely used. The slow increase in the 
uptake of cotrimoxazole has been asso-
ciated with delays in the dissemination 
of recommendations on its use (either 
in stand-alone guidelines or integrated 
into ART guidelines), problems with 
drug procurement and supply, poor 
health-care infrastructure for manag-
ing patients before ART and inadequate 
systems for monitoring and evaluation.30 
In addition to resolving these issues, the 
number of adults receiving cotrimoxa-
zole could also be increased by raising 
awareness of its benefits and by using 
indicators to monitor its uptake both 
globally and at the level of individual 
treatment programmes.38 Moreover, 
treatment programmes could also 
provide forecasts of the future annual 
demand for cotrimoxazole by using lo-
cal data on the number of individuals 
currently receiving or expected to start 
ART.30
Recently WHO and the Joint United 
Nations Programme on HIV/AIDS, as 
part of the Treatment 2.0 initiative,39 
prioritized identifying, retaining and 
caring for people earlier in the course 
of HIV infection as a way of improving 
clinical and programmatic outcomes. 
Indeed, implementing ART earlier 
within existing guidelines has had a 
considerable impact: in South Africa, 
mortality during the first year of ART 
declined from 8.9 to 5.6% as the me-
dian CD4 cell count at ART initiation 
increased from 68 to 113 cells/µL.40 
One way to facilitate earlier access to 
ART is through expanding HIV testing 
coverage. For generalized epidemics (i.e. 
when the prevalence of antenatal HIV 
infection is over 1%), WHO recom-
mends carrying out provider-initiated 
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particularly in patients with tubercu-
losis.42 Recent evidence suggests that 
community-based testing can identify 
individuals earlier in the course of HIV 
infection43 and increases knowledge of 
HIV status fourfold relative to health-
facility-based testing.44 Reductions in 
mortality, costs and the rate of new 
infections will also depend crucially on 
maintaining good links with personnel 
monitoring and caring for individuals 
before they receive ART, on maximizing 
the retention rate and on initiating ART 
as early as permitted by national guide-
lines. These actions will help achieve the 
Millennium Development Goals on HIV 
infection.45 Unfortunately, at present 
over 50% of HIV-infected individuals 
are lost to care between diagnosis and 
the start of ART.46–49 Giving free cotri-
moxazole can help increase the retention 
rate,50 provide an opportunity to assess 
an individual’s adherence to treatment 
before the start of ART51 and improve 
survival in those not on ART.52 Efforts to 
reduce early mortality in HIV-infected 
individuals and to increase retention 
rates in treatment programmes could 
be assisted by implementing intensi-
fied tuberculosis case-finding at every 
health-care visit and by providing free 
isoniazid to those with tuberculosis 
who do not have a cough, night sweats, 
weight loss or fever.53
For settings in which the health-
care infrastructure is limited, WHO rec-
ommends discontinuing cotrimoxazole 
in adults who show good adherence to 
ART, have secure access to treatment 
and who have not had a new WHO stage 
2, 3 or 4 disease event for at least 1 year.17 
Data from the one study that reported 
the estimated effect of cotrimoxazole 
on mortality after 1 year of combined 
treatment with ART indicate that there 
was no reduction in mortality after 
72 weeks of ART.28 For settings where 
the health-care infrastructure is good, 
WHO recommends discontinuing co-
trimoxazole in adults who have received 
ART for at least 6 months and have a 
CD4 cell count greater than 350 cells/
µL.17 The single study that provided an 
estimate of the effect of cotrimoxazole 
on mortality in adults on ART with a 
baseline CD4 cell count greater than 
350 cells/µL suggested that cotrimoxa-
zole had no effect.29
Two limitations of this systematic 
review were that most studies included 
had a short follow-up and that they 
did not include estimates of the effect 
of cotrimoxazole in adults with a high 
baseline CD4 cell count. Furthermore, 
only one randomized trial was identi-
fied. Although most studies did attempt 
to control for bias, prospective and ret-
rospective cohort studies are susceptible 
to unmeasured confounding. Also, none 
of the studies assessed adherence to 
cotrimoxazole and ART. Finally, since 
the cause of the death was not reported 
in any study, the precise mechanism of 
cotrimoxazole’s beneficial survival effect 
is not clear.
Although the data considered in 
this review were limited and results from 
an on-going trial are still awaited, our 
findings support current WHO recom-
mendations that the use of cotrimoxa-
zole should be scaled up in HIV-infected 
individuals starting or receiving ART. 
Further research is needed to determine 
the optimum duration of cotrimoxazole 
treatment in adults receiving ART for an 
HIV infection. ■
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Fig. 2. Forest plot of study and summary effect estimates for cotrimoxazole’s effect on 
death in adults with human immunodeficiency virus (HIV) infection receiving 
antiretroviral therapy (ART)










Note: The seven studies were included in the meta-analysis. The summary estimate of the treatment 
effect was calculated using a random-effects model. The risk is reported either as an odds ratio, a hazard 
ratio or a relative risk in the different studies. The centre of the squares represents the study point 
estimates while the horizontal lines represent the study 95% confidence intervals (CIs). The centre of the 
bottom quadrilateral represents the summary effect estimate, whereas its horizontal corners represent its 
95% CI.
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امللخص
تأثري كوترميوكسازول عىل الوفيات يف البالغني املصابني بفريوس العوز املناعي البرشي عىل العالج املضاد للفريوسات: استعراض منهجي 
وتحليل تلوي
الوفيات  من  حيد  كوتريموكسازول  كان  إذا  ما  حتديد  الغرض 
 )ART( للفريوسات  مضاد  لعالج  خيضعون  الذين  البالغني  يف 
 )HIV( البرشي  املناعي  العوز  بفريوس  اإلصابة  عدوى  لعالج 
استعراض  طريق  عن  الدخل  ومتوسطة  منخفضة  البلدان  يف 
منهجي وحتليل تلوي.
 Embaseو  PubMed بيانات  قواعد  يف  البحث  تم  الطرق 
عشوائية  عينات  تستخدم  والتي  للضبط  اخلاضعة  التجارب  عن 
قارنت  التي  واالسرتجاعية  االستباقية  األترابية  الدراسات  وعن 
بفريوس  املصابني  األشخاص  لدى  االعتالل  أو  الوفيات  بني 
عىل  وأث�ره  أكرب  أو  عامًا   13 أعامر  يف  البرشي  املناعي  العوز 
العالج  عىل  وأثره  للفريوسات  املضاد  والعالج  كوتريموكسازول 
أوتاوا  نيوكاسل  مقياس  استخدم  للفريوسات وحده. وتم  املضاد 
لتقييم اجلودة من أجل تقييم املجموعة املختارة، والعوامل املربكة 
وحتيز القياس. وتم تقييم عامل التحيز يف البحوث العلمية املنشورة 
ألن  احلساسية  حتليل  إجراء  وتم  وبيغ.  إيغر  اختبارات  باستخدام 
الدراسة.  نتائج  الرتبيعي أشار إىل تغايرية كبرية يف  التغاير  إحصاء 
وتم استخدام نموذج لآلثار العشوائية للتحليل التلوي.
االحتاملية  القيم  وكانت  دراس��ات.  تسع  تضمني  تم  النتائج 
تأثري  إىل  أشارت  التي  السبع  للدراسات  وإيغر  بيغ  الختبارات 
كوتريموكسازول عىل الوفيات هي 0.29 و0.49 عىل التوايل، مما 
يشري إىل عدم وجود عامل حتيز يف البحوث العلمية املنشورة. وكان 
املرتفعة  التغايرية  إىل  يشري  مما   ،%93.2 الرتبيعي  التغاير  إحصاء 
ونسبة  املتابعة  مدة  أن  احلساسية  حتليل  وأظهر  الدراسة.  نتائج  يف 
األفراد املصابني بفريوس العوز املناعي البرشي من املرحلة الثالثة 
العاملية عند خط األساس  الصحة  الرابعة وفق تصنيف منظمة  أو 
كوتريموكسازول  تأثري  تقييم  ملخص  وكان  التغايرية.  توضحا  مل 
عىل معدل حدوث الوفيات هو 0.42 )حدود ثقة %95: 0.29-
عام  من  ألقل  املشاركني  تابعت  الدراسات  معظم  وألن   .)0.61
وقف  املمكن  من  كان  إذا  ما  حتديد  املمكن  من  يكن  مل  واحد، 
بواسطة  املستحث  املناعي  االستنشاء  بعد  بأمان  كوتريموكسازول 
.)ART( العالج املضاد للفريوسات
البقاء  يف  كبرية  زيادة  حتقيق  يف  كوتريموكسازول  نجح  االستنتاج 
املناعي  العوز  بفريوس  املصابني  البالغني  لدى  احلياة  قيد  عىل 
البرشي مقارنة بغريه من العالج املضاد للفريوسات. وتوجد حاجة 
باستخدام  املثىل  العالج  مدة  لتحديد  األبحاث  من  املزيد  إلجراء 





























Effet du cotrimoxazole sur la mortalité des adultes infectés par le VIH sous thérapie antirétrovirale: examen systématique et 
méta-analyse
Objectif Déterminer si le cotrimoxazole réduit la mortalité des adultes 
recevant une thérapie antirétrovirale (TAR) contre l’infection par le virus 
de l’immunodéficience humaine (VIH) dans les pays à revenu faible et 
moyen, par un examen systématique et une méta-analyse.
Méthodes On a cherché dans PubMed et Embase des essais contrôlés 
randomisés et des études de cohorte prospectives et rétrospectives 
comparant la mortalité ou la morbidité chez des individus âgés de 13 ans 
et plus, infectés par le VIH, sous cotrimoxazole et TAR, et uniquement sous 
TAR. L’échelle d’évaluation de qualité Newcastle-Ottawa a été utilisée 
pour évaluer les biais de sélection, de confusion et de mesure. Le biais 
de publication a été évalué à l’aide des tests d’Egger et de Begg. Une 
analyse de sensibilité a été effectuée, car la statistique I-carré indiquait 
une hétérogénéité importante des résultats de l’étude. Un modèle à 
effets aléatoires a été utilisé pour la méta-analyse.
Résultats Neuf études ont été incluses. Les valeurs P de Begg et Egger 
pour les sept études rapportant l’effet du cotrimoxazole sur la mortalité 
étaient de 0,29 et de 0,49, respectivement, suggérant l’absence de biais 
de publication. La statistique I-carré était de 93,2%, indiquant une forte 
hétérogénéité des résultats de l’étude. L’analyse de sensibilité a montré 
que ni la durée du suivi ni le pourcentage de personnes atteintes par le 
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VIH au stade 3 et 4 de l’Organisation mondiale de la Santé, au moment 
de référence, n’expliquaient l’hétérogénéité. L’estimation sommaire 
de l’effet du cotrimoxazole sur le taux d’incidence des décès était de 
0,42 (intervalle de confiance de 95%: 0,29–0,61). Comme la plupart des 
études avaient suivi les participants pendant moins d’un an, il n’était 
pas possible de déterminer si l’administration de cotrimoxazole pouvait 
être interrompue en toute sécurité après reconstitution immunitaire 
induite par le TAR.
Conclusion Le cotrimoxazole augmentait significativement la survie des 
adultes infectés par le VIH sous traitement antirétroviral. Des recherches 
supplémentaires sont nécessaires pour définir la durée optimale du 
traitement par cotrimoxazole chez ces patients.
Резюме
Влияние котримоксазола на уровень смертности ВИЧ-инфицированных взрослых при проведении 
антиретровирусной терапии: систематический обзор и мета-анализ
Цель Посредством систематического обзора и мета-анализа 
определить влияние котримоксазола на снижение уровня 
смертности у взрослых при проведении антиретровирусной 
терапии (АРТ) вируса иммунодефицита человека (ВИЧ) в странах 
с низким и средним уровнем дохода.
Методы В базах данных публикаций PubMed и Embase был 
произведен поиск рандомизированных контролируемых 
испытаний, а также перспективных и ретроспективных 
обследований групп пациентов, в которых производилось 
сравнение уровня смертности и критических осложнений у 
ВИЧ-инфицированных лиц в возрасте ≥ 13 лет при применении 
котримоксазола в сочетании с АРТ или при проведении 
только АРТ. Для оценки выборки, дополнительных факторов и 
систематических ошибок измерений была использована шкала 
оценки качества Ньюкасл-Оттава. Систематические ошибки 
публикаций были оценены с помощью тестов Эггера и Бегга. 
Был проведен анализ чувствительности, поскольку метод 
сбалансированной оценки статистических данных показал 
значительную неоднородность результатов исследований. 
Для проведения мета-анализа была использована модель со 
случайными уровнями факторов.
Результаты Были учтены результаты девяти исследований. 
P-показатели в тестах Бегга и Эггера по семи исследованиям, 
в которых были приведены данные о влиянии котримоксазола 
на уровень смертности, составляли 0,29 и 0,49 соответственно, 
подтверждая тем самым отсутствие систематических 
ошибок в публикациях. Метод сбалансированной оценки 
статистических данных показал 93,2%, тем самым указывая 
на высокую неоднородность результатов исследований. 
Анализ чувствительности показал, что ни продолжительность 
последующего наблюдения, ни процентное соотношение 
лиц, инфицированных ВИЧ 3-ей или 4-ой стадии по шкале 
Всемирной Организации Здравоохранения, не объясняли данную 
неоднородность. Суммарная оценка влияния котримоксазола 
на коэффициент заболеваемости со смертельным исходом 
была равна 0,42 (95% доверительный интервал: 0,29–0,61). 
Поскольку в большей части исследований наблюдение за 
участниками осуществлялось не более одного года, было 
невозможно определить, можно ли без риска прекратить 
прием котримоксазола после иммунного восстановления, 
индуцированного АРТ. 
Вывод Котримоксазол значительно повысил уровень 
выживаемости ВИЧ-инфицированных взрослых при проведении 
АРТ. Необходимы дальнейшие исследования для определения 
оптимальной продолжительности терапии с применением 
котримоксазола у данных пациентов.
Resumen
Efecto de cotrimoxazol en la mortalidad de adultos infectados por el VIH que reciben tratamiento antirretrovírico: examen 
sistemático y metaanálisis.
Objetivo Determinar si cotrimoxazol reduce la mortalidad en adultos 
que reciben tratamiento antirretrovírico (TAR) para el virus de la 
inmunodeficiencia humana (VIH) en países de ingresos bajos y medios 
través de un examen sistemático y un metaanálisis.
Métodos Se realizó una búsqueda en PubMed y Embase para evaluar 
los ensayos aleatorizados controlados y los estudios de cohortes 
prospectivos y retrospectivos en los que se comparaban la mortalidad 
o la morbilidad en personas infectadas por el VIH con edades ≥13 años 
en tratamiento con cotrimoxazol y TAR, y solo con TAR. Se utilizó la Escala 
de Evaluación de la Calidad de Newcastle-Ottawa para evaluar el sesgo 
de selección, de confusión y de medición. El sesgo de publicación se 
evaluó mediante los tests de Egger y Begg. Se llevó a cabo un análisis 
de sensibilidad debido a que la estadística I-cuadrado indicó una 
heterogeneidad significativa en los resultados del estudio. El metanálisis 
siguió un modelo de efectos aleatorios.
Resultados Se incluyeron nueve estudios. Los valores de P de Begg y 
Egger para los siete estudios que recogieron el efecto de cotrimoxazol 
sobre la mortalidad fueron de 0,29 y 0,49, respectivamente, lo que 
sugiere que no existe sesgo de publicación. La estadística I-cuadrado fue 
del 93,2%, lo que indica una alta heterogeneidad en los resultados de los 
estudios. El análisis de sensibilidad mostró que dicha heterogeneidad no 
se debe ni a la duración de seguimiento ni al porcentaje de individuos 
con enfermedad por el VIH en los estadios 3 o 4 según la Organización 
Mundial de la Salud al inicio del estudio. La estimación global de los 
efectos del cotrimoxazol sobre la tasa de incidencia de la muerte fue de 
0,42 (intervalo de confianza del 95%: 0,29–0,61). Dado que la mayoría 
de los estudios realizaron un seguimiento de los participantes durante 
menos de 1 año, no fue posible determinar la posibilidad de suspender 
la administración de cotrimoxazol sin peligro después de la restauración 
inmunitaria inducida por la TAR.
Conclusión Cotrimoxazol aumentó significativamente la supervivencia 
en adultos infectados por el VIH que recibieron TAR. Es preciso llevar 
a cabo investigaciones adicionales con el objetivo de determinar la 
duración óptima del tratamiento con cotrimoxazol en estos pacientes.
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Table 1. Search strategies for publications on cotrimoxazole’s effect on mortality 
and morbidity in adults with human immunodeficiency virus (HIV) infection 
receiving antiretroviral therapy (ART)
Search 
number
PubMed search terms Search 
number
Embase search terms
1 HIV infections (MeSH term) 1 HIV
2 Acquired immunodeficiency 
syndrome (MeSH term)
2 AIDS
3 AIDS-related opportunistic 
infections (MeSH term)
3 Terms used in search 1 or 2
4 AIDS 4 Antiretroviral
5 HIV 5 Anti-retroviral
6 Terms used in search 1 or 2 or 3 
or 4 or 5
6 HAART
7 Antiretroviral therapy, highly 
active (MeSH term)
7 cART
8 Anti-infective agents (MeSH term) 8 ART
9 Antiretroviral 9 Terms used in search 4 or 5 or 6 
or 7 or 8
10 Anti-retroviral 10 Cotrimoxazole
11 HAART 11 Co-trimoxazole
12 ART 12 CPT
13 cART 13 Trimethoprim-sulfamethoxazole
14 Terms used in search 7 or 8 or 9 or 




15 Terms used in search 10 or 11 or 
12 or 13 or 14
16 Cotrimoxazole 16 Mortality
17 Co-trimoxazole 17 Death
18 CPT 18 Hospitalization
19 Terms used in search 15 or 16 or 
17 or 18
19 Adverse event
20 Mortality (MeSH term) 20 Terms used in search 16 or 17 or 
18 or 19
21 Death (MeSH term) 21 Terms used in searches 3 and 9 
and 15 and 20





27 Terms used in search 20 or 21 or 
22 or 23 or 24 or 25 or 26 or 27
28 Terms used in searches 6 and 14 
and 19 and 27
AIDS, acquired immunodeficiency syndrome; cART, combination antiretroviral therapy; CPT, cotrimoxazole 
preventive therapy; HAART, highly active antiretroviral therapy; MeSH, medical subject heading.
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Fig. 1. Flow diagram of article selection for systematic review of cotrimoxazole’s effect 
on mortality and morbidity in adults with human immunodeficiency virus (HIV) 


















A total of 33 articles were excluded:
6 articles excluded because they were not cohort or randomized
studies (4 comments on previously published articles, 
1 systematic review, and 1 clinical review);
22 articles excluded because the study population was 
not on antiretroviral therapy;
2 articles excluded because the intervention was not cotrimoxazole;
1 article excluded because the comparator was not off cotrimoxazole;
2 articles excluded because the outcome was not mortality, malaria,
WHO clinical stage 3 or 4 event, or an adverse event causing discontinuation.
64 duplicates
removed
WHO, World Health Organization. 
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